In malignant BC tissues or cell lines with high levels of RUNX2, endogenous SIRT6 expression is lower, further supporting the role of RUNX2 in suppressing SIRT6 and promoting glycolytic metabolism conducive to cancer progression [40]. The gene discussed is RUNX2; the disease is cancer.